Signet Therapeutics Successfully Certified as a National High-Tech Enterprise

Notification from Shenzhen Municipal Industry and Information Technology Bureau: The expert panel's review results for the first batch of National High-Tech Enterprise applications this year were announced last night. Signet Therapeutics, with its solid R&D foundation and groundbreaking scientific achievements, passed the National High-Tech Enterprise certification with high scores.

Awarded the "National High-tech Enterprise" qualification, SIGNET has officially entered the ranks of China's national high-tech enterprises. The recognition fully demonstrates that SIGNET’s comprehensive capabilities in technological innovation, intellectual property, pipeline R&D, and market prospects have gained national support and acknowledgment.

The recognition of National High-tech Enterprises has strict examination requirements for comprehensive indicators such as the core intellectual property rights owned by enterprises, R&D investment, R&D team building, the ability to transform scientific and technological achievements, organizational management capabilities, and growth potential. It has become an authoritative standard for evaluating the overall technological strength of enterprises in China and is one of the important honors for China's technology innovation-oriented enterprises.

Signet Therapeutics' successful recognition as a National High-tech Enterprise signifies that the company's breakthrough achievements and promising future in the field of innovative targeted cancer therapies have received official authoritative acknowledgment. This marks a new phase of development for the company’s R&D and technological capabilities. The recognition is not only an honor for Signet Therapeutics but also a responsibility.

Signet Therapeutics is the first company in China to develop innovative targeted cancer drugs based on organoid disease models and AI. Initially founded on the Harvard University campus, it was established in Shenzhen in 2020 and completed an angel round of financing of nearly 150 million yuan within a year. Signet is not only a transliteration of Signet but also adheres to the vision of "full of hope, studying things to gain knowledge." It leverages the critical role of organoid disease models that closely resemble patient genomic characteristics in efficacy evaluation and new target discovery, combined with AI screening, synthesis, and optimization of small molecule compounds, to develop first-in-class innovative targeted drugs. The company currently has three drug pipelines, with the first pipeline developing the world's first targeted drug for diffuse gastric cancer, which has now entered Phase I clinical trials. The company has a 1,200 square meter R&D facility and a 500 square meter experimental animal housing facility. Signet Therapeutics' disease model platform not only serves its own drug pipelines but also actively empowers large pharmaceutical companies in new drug development, contributing to the birth of more innovative drugs.